Verapamil-sustained release–based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: An INternational VErapamil SR-Trandolapril (INVEST) substudy
To access this article, please choose from the options below
This work was presented in part at the 2007 Annual Scientific Session of the American College of Cardiology in New Orleans, LA, on March 26, 2007.
This study was supported by grants from the University of Florida (Gainesville, FL) and Abbott Laboratories (Abbott Park, IL).
PII: S0002-8703(08)00225-1
doi:10.1016/j.ahj.2008.02.023
© 2008 Mosby, Inc. All rights reserved.
